Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.

Claret L, Pentafragka C, Karovic S, Zhao B, Schwartz LH, Maitland ML, Bruno R.

Cancer Chemother Pharmacol. 2018 Jul;82(1):49-54. doi: 10.1007/s00280-018-3587-7. Epub 2018 Apr 26.

PMID:
29700575
2.

A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.

Claret L, Jin JY, Ferté C, Winter H, Girish S, Stroh M, He P, Ballinger M, Sandler A, Joshi A, Rittmeyer A, Gandara D, Soria JC, Bruno R.

Clin Cancer Res. 2018 Jul 15;24(14):3292-3298. doi: 10.1158/1078-0432.CCR-17-3662. Epub 2018 Apr 23.

3.

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y.

Leuk Lymphoma. 2018 Apr;59(4):863-870. doi: 10.1080/10428194.2017.1359741. Epub 2017 Aug 9.

PMID:
28792260
4.

Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast.

Facius A, Krause A, Claret L, Bruno R, Lahu G.

J Clin Pharmacol. 2017 Aug;57(8):1042-1052. doi: 10.1002/jcph.885. Epub 2017 Apr 17.

PMID:
28419462
5.

Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to Mistry.

Claret L, Han K, Bruno R.

CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):225. doi: 10.1002/psp4.12163. Epub 2017 Apr 11. No abstract available.

6.

Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma.

Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, Abidoye O, Teng SL, Lin WT, Dayog S, Bruno R, Jin J, Girish S.

Clin Pharmacol Ther. 2017 Aug;102(2):305-312. doi: 10.1002/cpt.587. Epub 2017 Jun 9. Review.

PMID:
27981577
7.

Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.

Claret L, Zheng J, Mercier F, Chanu P, Chen Y, Rosbrook B, Yazdi P, Milligan PA, Bruno R.

Cancer Chemother Pharmacol. 2016 Sep;78(3):605-10. doi: 10.1007/s00280-016-3116-5. Epub 2016 Jul 28.

PMID:
27468922
8.

Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.

Han K, Claret L, Sandler A, Das A, Jin J, Bruno R.

BMC Cancer. 2016 Jul 13;16:473. doi: 10.1186/s12885-016-2455-2.

9.

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A.

Han K, Claret L, Piao Y, Hegde P, Joshi A, Powell JR, Jin J, Bruno R.

CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):352-8. doi: 10.1002/psp4.12064. Epub 2016 Jul 12.

10.

A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use.

Jonsson F, Ou Y, Claret L, Siegel D, Jagannath S, Vij R, Badros A, Aggarwal S, Bruno R.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):711-9. doi: 10.1002/psp4.12044. Epub 2015 Nov 20.

11.

Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients.

Claret L, Mercier F, Houk BE, Milligan PA, Bruno R.

Cancer Chemother Pharmacol. 2015 Sep;76(3):567-73. doi: 10.1007/s00280-015-2820-x. Epub 2015 Jul 22.

PMID:
26198314
12.

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS.

Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15.

13.

A Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant Pain.

Mercier F, Claret L, Prins K, Bruno R.

Pain Ther. 2014 Jun;3(1):31-44. doi: 10.1007/s40122-014-0023-5. Epub 2014 Feb 13.

14.

Assessment of tumor growth inhibition metrics to predict overall survival.

Claret L, Bruno R.

Clin Pharmacol Ther. 2014 Aug;96(2):135-7. doi: 10.1038/clpt.2014.112. No abstract available.

PMID:
25056390
15.

Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study results.

Claret L, Bruno R, Lu JF, Sun YN, Hsu CP.

Clin Pharmacol Ther. 2014 Apr;95(4):446-51. doi: 10.1038/clpt.2014.11. Epub 2014 Jan 17.

PMID:
24440965
16.

Evaluation of tumor size response metrics to predict survival in oncology clinical trials.

Bruno R, Mercier F, Claret L.

Clin Pharmacol Ther. 2014 Apr;95(4):386-93. doi: 10.1038/clpt.2014.4. Epub 2014 Jan 13. Review.

PMID:
24419563
17.

Reply to U.R. Mansmann et al and M.-W. An et al.

Claret L, Bruno R.

J Clin Oncol. 2013 Dec 1;31(34):4374-5. doi: 10.1200/JCO.2013.52.5733. Epub 2013 Oct 28. No abstract available.

PMID:
24166517
18.
19.

Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.

Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, Powell B, Bruno R.

J Clin Oncol. 2013 Jun 10;31(17):2110-4. doi: 10.1200/JCO.2012.45.0973. Epub 2013 May 6.

PMID:
23650411
20.

Model-based drug development in oncology: what's next?

Bruno R, Mercier F, Claret L.

Clin Pharmacol Ther. 2013 Apr;93(4):303-5. doi: 10.1038/clpt.2013.8.

PMID:
23511786
21.

The c-di-GMP phosphodiesterase VmpA absent in Escherichia coli K12 strains affects motility and biofilm formation in the enterohemorrhagic O157:H7 serotype.

Branchu P, Hindré T, Fang X, Thomas R, Gomelsky M, Claret L, Harel J, Gobert AP, Martin C.

Vet Immunol Immunopathol. 2013 Mar 15;152(1-2):132-40. doi: 10.1016/j.vetimm.2012.09.029. Epub 2012 Sep 26.

PMID:
23078901
22.

Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.

Claret L, Lu JF, Bruno R, Hsu CP, Hei YJ, Sun YN.

Clin Pharmacol Ther. 2012 Nov;92(5):631-4. doi: 10.1038/clpt.2012.78. Epub 2012 Aug 22.

PMID:
22910440
23.

Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.

Bruno R, Lindbom L, Schaedeli Stark F, Chanu P, Gilberg F, Frey N, Claret L.

CPT Pharmacometrics Syst Pharmacol. 2012 Dec 26;1:e19. doi: 10.1038/psp.2012.20.

24.

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.

Frances N, Claret L, Bruno R, Iliadis A.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1413-9. doi: 10.1007/s00280-011-1628-6. Epub 2011 Apr 8.

PMID:
21476101
25.

Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer.

Claret L, Lu JF, Sun YN, Bruno R.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1141-9. doi: 10.1007/s00280-010-1449-z. Epub 2010 Sep 25.

PMID:
20872147
26.

Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.

Lu JF, Claret L, Sutjandra L, Kuchimanchi M, Melara R, Bruno R, Sun YN.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1151-8. doi: 10.1007/s00280-010-1456-0. Epub 2010 Sep 25.

PMID:
20872145
27.

Complete genome sequence of Crohn's disease-associated adherent-invasive E. coli strain LF82.

Miquel S, Peyretaillade E, Claret L, de Vallée A, Dossat C, Vacherie B, Zineb el H, Segurens B, Barbe V, Sauvanet P, Neut C, Colombel JF, Medigue C, Mojica FJ, Peyret P, Bonnet R, Darfeuille-Michaud A.

PLoS One. 2010 Sep 17;5(9). pii: e12714. doi: 10.1371/journal.pone.0012714.

28.

A modeling and simulation framework to support early clinical drug development decisions in oncology.

Bruno R, Lu JF, Sun YN, Claret L.

J Clin Pharmacol. 2011 Jan;51(1):6-8. doi: 10.1177/0091270010376970. Epub 2010 Jul 13. No abstract available.

PMID:
20628172
29.

Role of decreased levels of Fis histone-like protein in Crohn's disease-associated adherent invasive Escherichia coli LF82 bacteria interacting with intestinal epithelial cells.

Miquel S, Claret L, Bonnet R, Dorboz I, Barnich N, Darfeuille-Michaud A.

J Bacteriol. 2010 Apr;192(7):1832-43. doi: 10.1128/JB.01679-09. Epub 2010 Jan 29.

30.

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, Fagerberg J, Bruno R.

J Clin Oncol. 2009 Sep 1;27(25):4103-8. doi: 10.1200/JCO.2008.21.0807. Epub 2009 Jul 27.

PMID:
19636014
31.
32.

The flagellar sigma factor FliA regulates adhesion and invasion of Crohn disease-associated Escherichia coli via a cyclic dimeric GMP-dependent pathway.

Claret L, Miquel S, Vieille N, Ryjenkov DA, Gomelsky M, Darfeuille-Michaud A.

J Biol Chem. 2007 Nov 16;282(46):33275-83. Epub 2007 Sep 7.

33.

Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra).

Claret L, Cox EH, McFadyen L, Pidgen A, Johnson PJ, Haughie S, Boolell M, Bruno R.

Pharm Res. 2006 Aug;23(8):1756-64.

PMID:
16841199
35.
36.

Oligomerization and activation of the FliI ATPase central to bacterial flagellum assembly.

Claret L, Calder SR, Higgins M, Hughes C.

Mol Microbiol. 2003 Jun;48(5):1349-55.

38.

The FliS chaperone selectively binds the disordered flagellin C-terminal D0 domain central to polymerisation.

Ozin AJ, Claret L, Auvray F, Hughes C.

FEMS Microbiol Lett. 2003 Feb 28;219(2):219-24.

39.
40.

Swarming-coupled expression of the Proteus mirabilis hpmBA haemolysin operon.

Fraser GM, Claret L, Furness R, Gupta S, Hughes C.

Microbiology. 2002 Jul;148(Pt 7):2191-201.

41.
42.

Information tools for exploratory data analysis in population pharmacokinetics.

Petricoul O, Claret L, Barbolosi D, Iliadis A, Puozzo C.

J Pharmacokinet Pharmacodyn. 2001 Dec;28(6):577-99.

PMID:
11999293
43.

A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin.

Claret L, Iliadis A, Macheras P.

J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):445-63.

PMID:
11768290
44.

Fractal volume of drug distribution: it scales proportionally to body mass.

Karalis V, Claret L, Iliadis A, Macheras P.

Pharm Res. 2001 Jul;18(7):1056-60.

PMID:
11496945
45.

The Escherichia coli histone-like protein HU regulates rpoS translation.

Balandina A, Claret L, Hengge-Aronis R, Rouviere-Yaniv J.

Mol Microbiol. 2001 Feb;39(4):1069-79.

46.
48.
49.

Regulation of HU alpha and HU beta by CRP and FIS in Escherichia coli.

Claret L, Rouviere-Yaniv J.

J Mol Biol. 1996 Oct 25;263(2):126-39.

PMID:
8913296
50.

Nonparametric density estimation applied to population pharmacokinetics.

Claret L, Iliadis A.

Math Biosci. 1996 Apr 1;133(1):51-68.

PMID:
8868572

Supplemental Content

Loading ...
Support Center